Therma Bright Inc. developer of its smart-enabled AcuVidTM COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to provide the following update for Its AcuVidTM COVID-19 Rapid Antigen Saliva Test. Therma continues to communicate with the FDA regarding its EUA application for its AcuVidTM COVID-19 Rapid Antigen Saliva Test. As well, Therma has sought and utilized advice from Ridge Global and FDA regulatory consultants to determine how best to accelerate the review of the AcuVidTM EUA application.

In addition to responding to the FDA's initial review and request for additional information, the Company expects to receive further feedback from the FDA once they review the submitted responses. Health Canada's application for approval under the Interim Order is moving along expeditiously with consistent feedback and answers between Therma and Health Canada's technical and medical reviewers. Therma announced that it has fielded several potential sales inquiries for the AcuVidTM COVID-19 Rapid Antigen Saliva Test.

Therma is currently discussing an order utilizing its self-certification CE mark for sales into Eastern Europe and other countries where the self-certification CE mark is accepted.